Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 233

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 233
---
 financial
information presented on a consolidated basis. The CODM uses consolidated net loss to measure segment profit or loss, to allocate resources
and assess performance. Further, the CODM reviews and utilizes functional expenses (research and development and general and administrative)
at the consolidated level to manage the Company’s operations and evaluate return on total assets in deciding whether to invest
in the development and expansion of the Company’s consolidated operations.

<div align='center'>F-42

[RESALE PROSPECTUS ALTERNATE PAGE]</div>

The information in this Prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

| PRELIMINARY 
 PROSPECTUS  | SUBJECT       
 TO COMPLETION | DATED                 
 OCTOBER        , 2025 |

<div align='center'>REVIUM RX.

Up to 37,625,790 Shares of Common Stock</div>

This Resale Prospectus
relates to the resale, from time to time, of up to an aggregate of 37,625,790 shares of our Common Stock, including 6,372,265 shares
of Common Stock issuable upon exercise of Investor Warrants. by the Selling Stockholders identified in this Resale Prospectus under the
caption “Selling Stockholders.” We are not selling any shares of our Common Stock under this Resale Prospectus, and we will
not receive any proceeds from the sale of Shares of Common Stock offered hereby by the Selling Stockholders, although we may receive
$7,413,436 from the exercise of the outstanding Investor Warrants, if they are exercised for cash.

Until our Common
Stock is quoted on the OTCQX or the OTCQB marketplace of OTC Market or until the shares of our Common Stock are listed on a national
securities exchange, the Company and the Selling Stockholders, or their respective transferees, pledgees, données or other successors-in-interest,
may sell their Shares pursuant to this Prospectus at a fixed price per share of $1.00. Notwithstanding our belief that upon the effective
date of this registration statement our Common Stock will satisfy the admission requirements for the OTCQB and our intention to make
application for quotation on the OTCQB Market, we